1. Opening remarks and introductions

2. Review of the May 3rd, 2014 minutes

3. OV21 (D. Provencher, H. MacKay)
   a. Update on sample accrual
   b. Discussion proposed collaboration with Charlie Gourlay (Edinburgh) for translational endpoint studies with OV21 samples
   c. Discussion of other possible studies for these samples

4. OV23 and proposed translation studies: an example for further immune-based clinical trials

5. Update on the TFRI COEUR program and approved studies

6. TFRI Immunotherapy program: focus on ovarian cancer

7. Varia